Development of biodegradable controlled release scleral systems of triamcinolone acetonide

Current Eye Research

Volumn 35, Issue 10, 2010, Pages 916-924

  Blatsios, G ^a,b   Tzimas, A S ^a   Mattheolabakis, G ^a   Panagi, Z ^a   Avgoustakis, K ^a   Gartaganis, S P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aqueous; Biodegradable; Controlled release; Eye; Poly(lactide); Scleral; Triamcinolone; Vitreous

Indexed keywords

MICROSPHERE; POLYLACTIDE; SOLVENT; TRIAMCINOLONE ACETONIDE;

ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BIODEGRADABILITY; CADAVER; CONCENTRATION (PARAMETERS); CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG RELEASE; EMULSION; ENCAPSULATION; EVAPORATION; EXPERIMENTAL RABBIT; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCLERA; SUSTAINED DRUG RELEASE; TABLET; VITREOUS BODY;

ABSORBABLE IMPLANTS; ANIMALS; AQUEOUS HUMOR; DELAYED-ACTION PREPARATIONS; DIFFUSION; EMULSIONS; GLUCOCORTICOIDS; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; RABBITS; SCLERA; TABLETS; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 77957092522     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.497599     Document Type: Article

References (56)

1. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52: 37-48. Review.
2. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002;21:145-151. Review.
3. Cunha-Vaz JG. The blood-ocular barriers: Past, present, and future. Doc Ophthalmol. 1997;93:149-157.
4. Janoria KG, Gunda S, Boddu SH, et al. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4: 371-388. Review.
5. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2005;139:972-982.
6. Maris PJ Jr, Correnti AJ, Donnenfeld ED. Intracameral triamcinolone acetonide as treatment for endothelial allograft rejection after penetrating keratoplasty. Cornea. 2008;27: 847-850.
7. Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther. 2008;24:245-248.
8. Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83:1225-1229. Review.
9. Mora P, Eperon S, Felt-Baeyens O, et al. Trans-scleral diffusion of triamcinolone acetonide. Curr Eye Res. 2005;30: 355-361.
10. Grady LT, Hays SE, King RH, et al. Drug purity profiles. J Pharm Sci. 1973;62:456-464.
11. Jermak CM, Dellacroce JT, Heffez J, et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52: 503-522. Review.
12. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
13. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
14. Jonas JB, Kreissig I, Kamppeter B, et al. Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases. Ophthalmologe. 2004;101:113-120. Review (in German). (Pubitemid 38295553)
15. Peyman GA, Moshfeghi DM. Intravitreal triamcinolone acetonide. Retina. 2004;24:488-490.
16. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmology. 2001;108: 765-772.
17. Abraldes MJ, Fernández M, Gómez-Ulla F. Intravitreal triamcinolone in diabetic retinopathy. Curr Diabetes Rev. 2009;5:18-25.
18. Chan RV, Seiff BD, Lincoff HA, et al. Rapid recovery of sympathetic ophthalmia with treatment augmented by intravitreal steroids. Retina. 2006;26:243-247.
19. Karacorlu M, Ozdemir H, Karacorlu S, et al. Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone. Int Ophthalmol. 2004;25:113-116.
20. Jaissle GB, Szurman P, Bartz-Schmidt KU. Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmologe. 2004;101:121-128. Review (in German).
21. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: Towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629-667. Review.
22. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: The past, the present, and the future. Surv Ophthalmol. 2008;53:139-149. Review.
23. Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol. 2006;17:235-244. Review.
24. Cekiç O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol. 2005;139:993-998.
25. Allen QB, Lowder CY, Meisler DM. Conjunctival necrosis following the administration of subconjunctival corticosteroid. Ophthalmic Surg Lasers. 1998;29:779-780.
26. Dal Canto AJ, Downs-Kelly E, Perry JD. Ptosis and orbital fat prolapse after posterior sub-Tenons capsule triamcinolone injection. Ophthalmology. 2005;112:1092-1097.
27. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110: 681-686.
28. Mason JO 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004;24:900-904.
29. Gillies MC, Islam FM, Zhu M, et al. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol. 2007;91:1323
30. Inatani M, Iwao K, Kawaji T, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: A multicenter retrospective case-control study. Am J Ophthalmol. 2008;145:676-681.
31. Jonas JB, Degenring R, Kreissig I, et al. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol. 2004;138:1054-1055. (Pubitemid 40040030)
32. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand. 2005;83:645-663. Review.
33. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;137: 560-562.
34. Spandau UH, Derse M, Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol. 2005;89:999-1003.
35. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90:999-1003. Epub 2006 Apr 5.
36. Tammewar AM, Cheng L, Kayikcioglu OR, et al. Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br J Ophthalmol. 2008;92:810-813. Epub 2008 Apr 17.
37. Hauser D, Bukelman A, Pokroy R, et al. Intravitreal triamcinolone for diabetic macular edema: Comparison of 1, 2, and 4 mg. Retina. 2008;28:825-830.
38. Cardillo JA, Souza-Filho AA, Oliveira AG. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Arch Soc Esp Oftalmol. 2006;81:675-677, 679-681.
39. Beeley NR, Rossi JV, Mello-Filho PA, et al. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J Biomed Mater Res A. 2005;73:437-444.
40. Kim YM, Lim JO, Kim HK, et al. A novel design of one side coated biodegradeable intrascleral implant for sustained release of triamcinolone acetonide. Eur J Pharm Biopharm. 2008;70:179-186.
41. Felt-Baeyens O, Eperon S, Mora P, et al. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int J Pharm. 2006;322:6-12.
42. Eperon S, Bossy-Nobs L, Petropoulos IK, et al. A biodegradable drug delivery system for the treatment of postoperative inflammation. Int J Pharm. 2008;352:240-247. Epub 2007 Nov 17.
43. Stivaktakis N, Nikou K, Panagi Z, et al. PLA and PLGA microspheres of β-galactosidase: Effect of formulation factors on protein antigenicity and immunogenicity. J Biomed Mater Res A. 2004;70:139-148.
44. Dhanaraju MD, Vema K, Jayakumar R, et al. Preparation and characterization of injectable microspheres of contraceptive hormones Int J Pharm. 2003;268:23-29.
45. Avgoustakis K, Nixon JR.Biodegradable controlled release tablets: III. Effect of polymer characteristics on drug release from heterogeneous poly(lactide-co-glycolide) matrices. Int J Pharm. 1993;99:247-252.
46. Mitchell K, Ford JL, Armstrong DJ, et al. The influence of substitution type on the performance of methylcellulose and hydroxypropylmethylcellulose in gels and matrices. Int J Pharm. 1993;100:143-154. (Pubitemid 23316326)
47. Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol.II. Philadelphia: WB Saunders, 1994; pp. 1092-1110.
48. Labbé A, Dupas B, Hamard P, et al. In vivo confocal microscopy study of blebs after filtering surgery. Ophthalmology. 2005;112:1979. Epub 2005 Sep 12.
49. Yarangümeli A, Köz OG, Kural G. Encapsulated blebs following primary standard trabeculectomy: Course and treatment. J Glaucoma. 2004;13:251-255.
50. DHermies F, Korobelnik JF, Chauvaud D, et al. Scleral and episcleral histological changes related to encircling explants in 20 eyes. Acta Ophthalmol Scand. 1999;77:279-285.
51. Okabe J, Kimura H, Kunou N, et al. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci. 2003;44:740-744.
52. Wollensak G, Iomdina E. Crosslinking of scleral collagen in the rabbit using glyceraldehyde. J Cataract Refract Surg. 2008;34:651-656.
53. Stewart JM, Schultz DS, Lee OT, et al. Exogenous collagen cross-linking reduces scleral permeability: Modeling the effects of age-related cross-link accumulation. Invest Ophthalmol Vis Sci. 2009;50:352-357.
54. Gasiorowski JZ, Russell P. Biological properties of trabecular meshwork cells. Exp Eye Res. 2009;88:671-675.
55. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82: 479-487.
56. Sancho-Tello M, Muriach M, Barcia J, et al. Chronic alcohol feeding induces biochemical, histological, and functional alterations in rat retina. Alcohol Alcohol. 2008;43:254-260. Epub 2008 Feb 27.